Amoclav Suspension Indications/Uses

156.25 mg/5 mL & 312.5 mg/5 mL powder for oral suspension: Co-amoxiclav is indicated for the treatment of the following infections in adults and children (see Dosage & Administration, Precautions and Pharmacology: Pharmacodynamics under Actions): Acute bacterial sinusitis (adequately diagnosed); Acute otitis media; Acute exacerbations of chronic bronchitis (adequately diagnosed); Community acquired pneumonia; Cystitis; Pyelonephritis; Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis; Bone and joint infections, in particular osteomyelitis.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
228.5 mg/5 mL & 457 mg/5 mL powder for suspension: For the short-term treatment of the following infections caused by susceptible microorganisms: Upper respiratory tract infections (including ENT infections): Tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections: Acute and chronic bronchitis, pneumonia, lung abscess.
Genito-urinary tract and abdominal infections: Cystitis, urethritis, pyelonephritis, female genital infections, septic abortion, pelvic or puerperal sepsis, intra-abdominal sepsis.
Skin and skin structure infections: Furuncle and abscess, cellulitis, wound infections.
Bone and joint infections: Osteomyelitis.
Dental infection: Dentoalveolar abscess.
Other infections: Septicemia, peritonitis, post-surgical infections.
Step down treatment for infections due to susceptible organisms, initially given antimicrobial therapy, particularly parenteral Co-amoxiclav.
642.9 mg/5 mL powder for oral suspension: For the short-term treatment of bacterial infections in pediatric patients at the following sites when caused by Co-Amoxiclav-susceptible microorganisms: Upper respiratory tract infections (including ENT infections) e.g., recurrent or persistent acute otitis media due to Streptococcus pneumoniae (penicillin minimum inhibitory concentration (MIC) ≤4 μg/mL), Haemophilus influenzae and Moraxella catarrhalis.
Such patients are often characterized by antibiotic exposure for acute otitis media within the preceding 3 months, and are either aged ≤2 years or attend daycare; tonsillopharyngitis and sinusitis typically caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
Lower respiratory tract infections e.g., lobar and bronchopneumonia typically caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Skin and soft tissue infections typically caused by Staphylococcus pyogenes.